Form 4: Borgeson Sells Recursion Pharmaceuticals Shares

Blake Borgeson, a director at Recursion Pharmaceuticals, Inc., has reported the sale of 40,000 shares of Class A Common Stock.

Summary

• Blake Borgeson, a director of Recursion Pharmaceuticals, Inc. (RXRX), has reported a transaction involving the sale of 40,000 shares of Class A Common Stock.
• The sale occurred on July 7, 2026, with a weighted average sale price of $3.9625 per share, with individual sale prices ranging from $3.95 to $4.00.
• This transaction was executed as part of a Rule 10b5-1 trading plan adopted by Mr. Borgeson on August 31, 2025.
• Following this transaction, Mr. Borgeson beneficially owns 6,218,287 shares of Class A Common Stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the director's sale of shares, although the pre-planned nature of the transaction mitigates some concern.

Negatives

• Director sale of a significant number of shares (40,000) could be perceived negatively by the market.

Risks

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which is designed to mitigate insider trading concerns, but the market may still interpret any sale by a director as a negative signal.

Future Outlook

No forward-looking statements or guidance are present in this filing, as it solely reports a past transaction.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, can sometimes lead to short-term market reactions. However, the context of the sale (pre-planned) and the continued substantial beneficial ownership by the director are important factors for investors to consider.

Stakeholder Impact

• Shareholders: May interpret the sale as a signal of reduced confidence by the director, potentially impacting short-term stock price. However, the 10b5-1 plan suggests a pre-determined strategy rather than a reaction to new negative information.
• Management: The transaction is a standard disclosure for a director and does not directly impact other management personnel unless they are also involved in similar plans or transactions.

Next Steps

• Continued monitoring of insider transactions for any further sales or purchases by directors and officers.
• Analysis of Recursion Pharmaceuticals' overall financial health and strategic progress to contextualize insider trading activity.

Key Dates

Keywords

Form 4, Insider Trading, Stock Sale, Recursion Pharmaceuticals, RXRX, Blake Borgeson, Rule 10b5-1, Beneficial Ownership